grant
Advancing novel therapeutics and translational science to close the survivorship gap in pediatric, adolescent and young adult (AYA) lymphoma
NIHUS FederalResearch GrantFY20250-11 years oldAccelerationActive Follow-upAdolescent and Young AdultAdult LymphomaAfter CareAfter-TreatmentAftercareAntibody-drug conjugatesAwardBiologyBlood DiseasesBody TissuesCD30CancersCell TherapyChemotherapy and RadiationChemotherapy and/or radiationChildChild YouthChildhoodChildhood LeukemiaChildhood LymphomaChildren (0-21)Children's Oncology GroupClinicalClinical ResearchClinical StudyClinical TrialsDataData CommonsEnsureEpidemiological dataEpidemiology dataGerminoblastic SarcomaGerminoblastomaGoalsHematologic DiseasesHematological DiseaseHematological DisorderHematopoietic Cell TumorHematopoietic MalignanciesHematopoietic NeoplasmsHematopoietic Neoplasms including LymphomasHematopoietic TumorHematopoietic and Lymphoid Cell NeoplasmHematopoietic and Lymphoid NeoplasmsHodgkin DiseaseHodgkin DisorderHodgkin lymphomaHodgkin'sHodgkin's LymphomaHodgkin's diseaseHodgkins lymphomaImmune mediated therapyImmunologically Directed TherapyImmunotherapyIncidenceInfrastructureInstitutionKI-1LeadLeadershipLinkLymphomaMalignant Hematopoietic NeoplasmMalignant LymphogranulomaMalignant LymphomaMalignant NeoplasmsMalignant TumorMorbidityMorbidity - disease ratePb elementPediatric LeukemiaPediatric LymphomaPediatric Oncology GroupPopulationPositionPositioning AttributeProductivityRecurrent diseaseRefractory DiseaseRegimenRelapseRelapsed DiseaseReticulolymphosarcomaRiskRoleScientistSpecialistTNFRSF8TNFRSF8 geneTimeTissuesTranslational ResearchTranslational ScienceWorkactive followupbiobankbiorepositoryblood cancerblood disordercancer microenvironmentcancer of bloodcancer of the bloodcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular targetingcellular therapeuticcellular therapychemo/radiation therapychemotherapy and radiotherapychildren with leukemiacollaborative trialcurative interventioncurative therapeuticcurative therapycurative treatmentsepidemiologic dataexperiencefollow upfollow-upfollowed upfollowupheavy metal Pbheavy metal leadimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimprovedkidsleukemia in childrenleukemia/lymphomalymphoma/leukemiamalignancyneoplasm/cancernew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyolder adultolder adulthoodpediatricpost treatmentprogramsradiation or chemotherapyresponserisk stratificationsocial rolestratify risksuccesssurvivorshiptimelinetranslation researchtranslational investigationtrial designtrial enrollmenttumor microenvironmentyoungster
Description preview
Hodgkin Lymphoma (HL) has its first incidence peak in the adolescent and young adults (AYA) years. Despite the success of chemotherapy and radiation in younger children and older adults, there has been a gap in survival for AYA. In addition, this group is at risk for decreased access to clinical trials. With the availability of antibody drug…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click